Lundbeck Board Chair Dorothea Wenzel to Step Down in 2027

H. Lundbeck A/S, the Danish pharmaceutical company Lundbeck, has announced upcoming changes to its Board of Directors. Dorothea Wenzel, the current Chair of the Board, has informed the board of her intention to step down. Her departure is scheduled to take place in connection with the Annual General Meeting (AGM) in 2027.

Following Wenzel's resignation, the Lundbeck Board intends to appoint Lars Fruergaard Jørgensen as the new Chair. Jørgensen, who currently serves as the company's CEO, is expected to transition into the role after the 2027 AGM. To facilitate a smooth handover, he will join the Board as an observer effective November 10, 2026, prior to his formal election.

Wenzel has held the position of Chair for several years, overseeing the company's strategic direction in developing treatments for brain diseases. Jørgensen has been CEO of Lundbeck since 2018, leading the company's research and development efforts and global expansion.

The planned leadership transition indicates Lundbeck's focus on long-term strategic continuity and succession planning. The company continues its commitment to advancing treatments for central nervous system disorders.